Why is early engagement with EMA, payers, KOLs, and patient groups so important?
What’s Inside the Q&A:
Strategic Stakeholder Engagement Timeline – When and how to connect with EMA, payers, KOLs, and patient groups throughout your development journey.
Regulatory Scientific Advice Process – How EMA and national Health Agency consultations work and what guidance you can expect at each development stage.
European Payer Landscape Navigation – Understanding HTA bodies like NICE, HAS, and G-BA, plus new parallel consultation opportunities with EMA.
Risk Mitigation Through Early Planning – Real scenarios showing how proactive engagement prevents costly late-stage program changes and market access barriers.
